← Back to patent-cliff list
TPM-502
Tier C — Watch / tradeTPM-502
Topas Therapeutics GmbH
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Updating
Indications (approved)：乳糜泻
Regional status
US
-
EU
Phase II
2022-12-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TPM-502?
Approved indications include: 乳糜泻.
When does the TPM-502 patent expire?
No public expiry year is available for TPM-502 yet; this page updates once verified.
How do I get a quote for TPM-502 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21